Supplementary Materials

Table S1. Number of exacerbations during dosing periods (averaged across all 4-weekly dosing periods within the DREAM study) according to baseline blood eosinophil count.

| Baseline blood eosinophil count | Dosing period | Placebo (n=155) | 75 mg (n=153) | 250 mg (n=152) | 750 mg (n=156) |
|---------------------------------|---------------|----------------|---------------|----------------|----------------|
| <300 cells/µL                   | First 2 weeks (Days 1–14) | n | 69 | 84 | 82 | 79 |
|                                 |               | Total exacerbations, n | 46 | 45 | 59 | 30 |
|                                 |               | Mean no. of exacerbations per patient | 0.67 | 0.54 | 0.72 | 0.38 |
|                                 |               | ≥1 exacerbation, n (%) | 29 (42) | 28 (33) | 32 (39) | 20 (25) |
|                                 | Second 2 weeks (Days 15–28) | n | 69 | 84 | 82 | 79 |
|                                 |               | Total exacerbations, n | 37 | 47 | 62 | 32 |
|                                 |               | Mean no. of exacerbations per patient | 0.54 | 0.56 | 0.76 | 0.41 |
|                                 |               | ≥1 exacerbation, n (%) | 25 (36) | 27 (32) | 35 (43) | 23 (29) |
|                                 |               | ≥1 additional exacerbation | 15 (22) | 18 (21) | 24 (29) | 17 (22) |
|                                 |               | ≥2 additional exacerbations | 4 (6) | 5 (6) | 9 (11) | 2 (3) |
|                                 |               | ≥3 additional exacerbations | 2 (3) | 3 (4) | 4 (5) | 1 (1) |
| ≥300 cells/µL                   | First 2 weeks (Days 1–14) | n | 86 | 69 | 70 | 77 |
|                                 |               | Total exacerbations, n | 91 | 22 | 25 | 39 |
|                                 |               | Mean no. of exacerbations per patient | 1.06 | 0.32 | 0.36 | 0.51 |
|                                 |               | ≥1 exacerbation, n (%) | 46 (53) | 16 (23) | 20 (29) | 26 (34) |
|                                 | Second 2 weeks (Days 15–28) | n | 86 | 69 | 70 | 77 |
|                                 |               | Total exacerbations, n | 99 | 34 | 30 | 45 |
|                                 |               | Mean no. of exacerbations per patient | 1.15 | 0.49 | 0.43 | 0.58 |
|                                 |               | ≥1 exacerbation, n (%) | 47 (55) | 23 (33) | 27 (39) | 24 (31) |
|                                 |               | ≥1 additional exacerbation | 29 (34) | 16 (23) | 14 (20) | 15 (19) |
|                                 |               | ≥2 additional exacerbations | 14 (16) | 4 (6) | 1 (1) | 6 (8) |
|                                 |               | ≥3 additional exacerbations | 8 (9) | 1 (1) | 0 | 2 (3) |

Excludes 33 exacerbations (4% of all exacerbations: 31 occurred more than 28 days after the most recent dose; 2 occurred on the day of the first dose).
Table S2. Mean eDiary-assessed peak expiratory flow (L/min) during the individual dosing periods of the DREAM study

| Dosing period | Placebo (n=155) | 75 mg (n=153) | Mepolizumab 250 mg (n=152) | Mepolizumab 750 mg (n=156) |
|---------------|----------------|---------------|----------------------------|--------------------------|
| **Weeks 1–4** |                |               |                            |                          |
|               | **n**          | **Mean (SD)** | **Mean (SD)**              | **Mean (SD)**            |
| **First 2 weeks** | 146           | 270.1 (102.2) | 271.6 (112.2)              | 287.3 (120.8)            |
| **Next 2 weeks** | 141           | 273.7 (100.4) | 280.6 (114.1)              | 286.0 (123.2)            |
| Mean change (SD) | 3.5 (35.9)     | 9.0 (28.1)    | -1.3 (32.7)                | 3.6 (27.9)               |
| **Weeks 5–8** |                |               |                            |                          |
|               | **n**          | **Mean (SD)** | **Mean (SD)**              | **Mean (SD)**            |
| **First 2 weeks** | 139           | 276.0 (106.8) | 280.1 (118.2)              | 293.1 (126.7)            |
| **Next 2 weeks** | 140           | 278.4 (113.5) | 282.3 (119.4)              | 289.5 (125.7)            |
| Mean change (SD) | 2.4 (27.9)     | 2.2 (25.8)    | -3.6 (25.1)                | -1.1 (26.4)              |
| **Weeks 9–12** |                |               |                            |                          |
|               | **n**          | **Mean (SD)** | **Mean (SD)**              | **Mean (SD)**            |
| **First 2 weeks** | 137           | 276.3 (111.2) | 282.1 (116.6)              | 305.7 (129.3)            |
| **Next 2 weeks** | 134           | 272.0 (111.0) | 282.3 (117.3)              | 299.6 (124.6)            |
| Mean change (SD) | -4.3 (32.8)    | 0.2 (25.7)    | -6.1 (23.5)                | -1.6 (24.4)              |
| **Weeks 13–16** |                |               |                            |                          |
|               | **n**          | **Mean (SD)** | **Mean (SD)**              | **Mean (SD)**            |
| **First 2 weeks** | 133           | 275.7 (116.0) | 280.2 (120.2)              | 288.5 (124.4)            |
| **Next 2 weeks** | 131           | 274.4 (117.1) | 276.3 (118.8)              | 282.8 (124.2)            |
| Mean change (SD) | -1.3 (24.2)    | -3.9 (20.4)   | -5.7 (25.2)                | -1.4 (21.5)              |
| **Weeks 17–20** |                |               |                            |                          |
|               | **n**          | **Mean (SD)** | **Mean (SD)**              | **Mean (SD)**            |
| **First 2 weeks** | 131           | 278.3 (114.9) | 287.2 (113.8)              | 288.9 (129.4)            |
| **Next 2 weeks** | 130           | 279.8 (115.1) | 288.3 (119.5)              | 286.0 (128.0)            |
| Mean change (SD) | 1.5 (32.8)     | 1.1 (25.9)    | -2.8 (22.4)                | -1.7 (21.3)              |
| **Weeks 21–24** |                |               |                            |                          |
|               | **n**          | **Mean (SD)** | **Mean (SD)**              | **Mean (SD)**            |
| **First 2 weeks** | 118           | 289.0 (114.2) | 285.4 (122.1)              | 291.6 (132.1)            |
| **Next 2 weeks** | 122           | 286.1 (114.8) | 279.0 (119.8)              | 288.3 (131.3)            |
| Mean change (SD) | -2.9 (24.5)    | -6.4 (21.2)   | -3.3 (19.2)                | 2.0 (20.8)               |
| **Weeks 25–28** |                |               |                            |                          |
|               | **n**          | **Mean (SD)** | **Mean (SD)**              | **Mean (SD)**            |
| **First 2 weeks** | 129           | 288.0 (114.2) | 285.4 (122.1)              | 291.6 (132.1)            |
| **Next 2 weeks** | 122           | 286.1 (114.8) | 279.0 (119.8)              | 288.3 (131.3)            |
| Mean change (SD) | -2.9 (24.5)    | -6.4 (21.2)   | -3.3 (19.2)                | 2.0 (20.8)               |
### Table: Mean (SD) of Mood Scores

| Weeks       | n  | First 2 weeks | Mean (SD) | Next 2 weeks | Mean (SD) | Mean change (SD) | Mean (SD) | Next 2 weeks | Mean (SD) | Mean change (SD) | Mean (SD) |
|-------------|----|---------------|-----------|--------------|-----------|-----------------|-----------|--------------|-----------|-----------------|-----------|
| **First 2 weeks** |    |               |           |              |           |                 |           |              |           |                 |           |
|              |    |               | 283.1 (113.8) | 280.1 (121.7) | 290.0 (128.3) | 282.4 (124.8) |           |              |           |                 |           |
| **Next 2 weeks** |    |               | 281.0 (113.8) | 278.2 (118.1) | 291.6 (128.0) | 277.2 (121.8) | -2.0 (23.6) | -1.9 (26.7) | 1.6 (18.6) | -5.2 (22.5)    |           |
| **Mean change (SD)** |    |               | -0.6 (29.8)   | -4.0 (22.4)   | 0.1 (18.9)   | -0.1 (20.1)    |           |              |           |                 |           |
| **Weeks 29–32** |    |               | 123        | 123          | 129        | 127            |           |              |           |                 |           |
| **First 2 weeks** |    |               | 283.4 (111.0) | 270.5 (109.3) | 296.1 (130.9) | 283.7 (124.5) |           |              |           |                 |           |
| **Next 2 weeks** |    |               | 282.8 (114.4) | 266.5 (103.4) | 296.2 (134.8) | 283.6 (123.8) | -0.6 (29.8) | -4.0 (22.4) | 0.1 (18.9) | -0.1 (20.1)    |           |
| **Mean change (SD)** |    |               | -1.9 (26.7)   | -4.0 (22.4)   | 0.1 (18.9)   | -0.1 (20.1)    |           |              |           |                 |           |
| **Weeks 33–36** |    |               | 117        | 121          | 128        | 120            |           |              |           |                 |           |
| **First 2 weeks** |    |               | 289.8 (114.5) | 269.8 (115.3) | 296.8 (134.3) | 288.1 (125.0) |           |              |           |                 |           |
| **Next 2 weeks** |    |               | 287.7 (114.7) | 269.3 (113.4) | 296.1 (134.7) | 289.3 (128.7) | -2.1 (24.4) | -0.4 (17.0) | -0.7 (18.0) | 1.2 (20.1)    |           |
| **Mean change (SD)** |    |               | -3.5 (27.6)   | -1.9 (20.8)   | 0.2 (21.1)   | 1.3 (25.9)     |           |              |           |                 |           |
| **Weeks 37–40** |    |               | 118        | 120          | 121        | 121            |           |              |           |                 |           |
| **First 2 weeks** |    |               | 287.9 (111.9) | 274.7 (117.4) | 300.4 (131.3) | 287.6 (126.9) |           |              |           |                 |           |
| **Next 2 weeks** |    |               | 284.4 (111.9) | 272.8 (116.7) | 299.2 (131.7) | 288.9 (128.0) | -3.5 (27.6) | -1.9 (23.6) | -2.2 (19.6) | 1.2 (21.3)    |           |
| **Mean change (SD)** |    |               | -2.9 (23.6)   | -1.9 (23.6)   | -2.2 (19.6) | 1.2 (21.3)     |           |              |           |                 |           |
| **Weeks 41–44** |    |               | 118        | 120          | 123        | 121            |           |              |           |                 |           |
| **First 2 weeks** |    |               | 283.7 (112.5) | 275.3 (114.5) | 295.7 (127.5) | 287.1 (129.9) |           |              |           |                 |           |
| **Next 2 weeks** |    |               | 284.0 (111.4) | 272.3 (115.8) | 293.5 (131.0) | 288.3 (128.8) | 0.2 (21.1)   | -2.9 (23.6) | -2.2 (19.6) | 1.2 (21.3)    |           |
| **Mean change (SD)** |    |               | -1.6 (24.6)   | -1.2 (21.1)   | -1.2 (21.4) | 0.8 (31.7)     |           |              |           |                 |           |
| **Weeks 45–48** |    |               | 115        | 109          | 126        | 117            |           |              |           |                 |           |
| **First 2 weeks** |    |               | 280.2 (107.7) | 276.2 (110.9) | 298.7 (134.4) | 287.7 (124.3) |           |              |           |                 |           |
| **Next 2 weeks** |    |               | 278.6 (107.6) | 275.0 (110.5) | 297.5 (133.4) | 288.5 (126.8) | -1.6 (24.6) | -1.2 (21.1) | -1.2 (21.4) | 0.8 (31.7)    |           |
| **Mean change (SD)** |    |               | -1.9 (22.1)   | -1.9 (22.1)   | -0.7 (15.5) | 0.0 (21.4)     |           |              |           |                 |           |
| **Weeks 49–52** |    |               | 106        | 113          | 113        | 111            |           |              |           |                 |           |
| **First 2 weeks** |    |               | 285.1 (113.8) | 278.0 (114.9) | 294.0 (130.3) | 293.3 (128.1) |           |              |           |                 |           |
| **Next 2 weeks** |    |               | 283.5 (117.6) | 276.1 (111.6) | 293.4 (134.1) | 293.3 (129.7) | -1.5 (22.7) | -1.9 (22.1) | -0.7 (15.5) | 0.0 (21.4)    |           |
| **Mean change (SD)** |    |               | -1.9 (22.1)   | -1.9 (22.1)   | -0.7 (15.5) | 0.0 (21.4)     |           |              |           |                 |           |

Patients with ≥7 days eDiary data for both 2-week periods were included in the analysis of each individual dosing period.

SD, standard deviation.
| Dosing period | Placebo (n=155) | 75 mg (n=153) | Mepolizumab | 250 mg (n=152) | 750 mg (n=156) |
|---------------|----------------|----------------|-------------|----------------|----------------|
| **Weeks 1–4** |                |                |             |                |                |
| n             | 147            | 142            | 149         | 147            |
| **First 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.4 (2.5)      | 2.1 (2.6)      | 2.3 (2.6)   | 2.3 (2.5)      |
| **Next 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.1 (2.5)      | 1.9 (2.6)      | 2.2 (2.7)   | 2.2 (2.7)      |
| Mean change (SD) | -0.4 (1.0)   | -0.2 (0.7)     | 0.1 (1.0)   | -0.1 (0.8)     |
| **Weeks 5–8** |                |                |             |                |                |
| n             | 142            | 141            | 142         | 145            |
| **First 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.0 (2.3)      | 1.7 (2.1)      | 1.9 (2.4)   | 2.0 (2.6)      |
| **Next 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.1 (2.5)      | 1.6 (2.4)      | 2.0 (2.5)   | 2.1 (2.8)      |
| Mean change (SD) | 0.1 (0.8)     | -0.1 (0.7)     | 0.0 (0.6)   | 0.0 (0.8)      |
| **Weeks 9–12** |                |                |             |                |                |
| n             | 137            | 135            | 136         | 137            |
| **First 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.0 (2.6)      | 1.5 (2.4)      | 1.9 (2.6)   | 1.9 (2.8)      |
| **Next 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.0 (3.0)      | 1.5 (2.4)      | 1.9 (2.5)   | 1.9 (2.9)      |
| Mean change (SD) | 0.1 (0.9)     | -0.0 (0.5)     | -0.0 (0.6)  | 0.0 (0.7)      |
| **Weeks 13–16** |                |                |             |                |                |
| n             | 133            | 133            | 135         | 138            |
| **First 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.0 (2.9)      | 1.6 (2.5)      | 2.0 (2.5)   | 2.0 (2.9)      |
| **Next 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.0 (2.8)      | 1.6 (2.6)      | 2.0 (2.6)   | 2.0 (3.0)      |
| Mean change (SD) | 0.0 (0.7)     | 0.0 (0.4)      | 0.1 (0.6)   | 0.0 (0.4)      |
| **Weeks 17–20** |                |                |             |                |                |
| n             | 132            | 130            | 133         | 134            |
| **First 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.0 (3.0)      | 1.5 (2.5)      | 1.9 (2.6)   | 1.9 (2.8)      |
| **Next 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 1.9 (2.9)      | 1.5 (2.9)      | 1.8 (2.5)   | 1.9 (2.8)      |
| Mean change (SD) | -0.1 (0.8)    | 0.0 (1.1)      | -0.1 (0.6)  | -0.0 (0.6)     |
| **Weeks 21–24** |                |                |             |                |                |
| n             | 118            | 122            | 126         | 134            |
| **First 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 1.9 (2.7)      | 1.6 (3.0)      | 2.0 (2.6)   | 2.0 (2.9)      |
| **Next 2 weeks** |          |                |             |                |                |
| Mean (SD)     | 2.0 (2.9)      | 1.6 (3.0)      | 1.9 (2.7)   | 2.0 (3.0)      |
| Mean change (SD) | 0.1 (0.7)     | -0.0 (0.4)     | -0.0 (0.5)  | 0.1 (0.7)      |
| **Weeks 25–28** |                |                |             |                |                |
| n             | 130            | 122            | 127         | 126            |
| **First 2 weeks** |          |                |             |                |                |

Table S3. Mean eDiary-assessed rescue medication use* during the individual dosing periods of the DREAM study.
| Weeks 29–32 | n | First 2 weeks | Mean (SD) | Next 2 weeks | Mean (SD) | Mean change (SD) | Mean (SD) | Next 2 weeks | Mean (SD) | Mean change (SD) |
|-------------|---|---------------|-----------|-------------|-----------|-----------------|-----------|-------------|-----------|-----------------|
|             |   |               | 124       | 123         | 129       | 127             |           |             |           |                 |
|             |   |               | 1.9 (2.8) | 1.7 (3.1)   | 1.9 (2.7) | 2.0 (2.7)       |           |             |           |                 |
|             |   |               | 2.0 (3.0) | 1.7 (3.1)   | 1.9 (2.7) | 2.0 (3.1)       |           |             |           |                 |
|             |   |               | 0.0 (0.8) | -0.0 (0.4)  | 0.0 (0.4) | -0.0 (1.0)      |           |             |           |                 |
| Weeks 33–36 | n |               | 120       | 121         | 128       | 120             |           |             |           |                 |
|             |   |               | 2.0 (3.0) | 1.6 (3.0)   | 1.9 (2.7) | 2.0 (3.0)       |           |             |           |                 |
|             |   |               | 2.1 (3.2) | 1.7 (3.1)   | 1.8 (2.6) | 2.0 (3.1)       |           |             |           |                 |
|             |   |               | 0.2 (1.0) | 0.0 (0.5)   | -0.1 (0.6)| 0.0 (0.4)       |           |             |           |                 |
| Weeks 37–40 | n |               | 119       | 120         | 122       | 121             |           |             |           |                 |
|             |   |               | 1.9 (3.0) | 1.7 (3.1)   | 1.7 (2.6) | 1.9 (3.1)       |           |             |           |                 |
|             |   |               | 2.0 (3.0) | 1.7 (3.0)   | 1.7 (2.6) | 2.0 (3.1)       |           |             |           |                 |
|             |   |               | 0.1 (0.7) | -0.0 (0.5)  | 0.0 (0.6) | 0.1 (0.5)       |           |             |           |                 |
| Weeks 41–44 | n |               | 119       | 120         | 124       | 121             |           |             |           |                 |
|             |   |               | 2.0 (3.1) | 1.6 (3.1)   | 1.7 (2.5) | 1.9 (2.7)       |           |             |           |                 |
|             |   |               | 2.1 (3.2) | 1.6 (3.0)   | 1.7 (2.5) | 1.9 (2.7)       |           |             |           |                 |
|             |   |               | 0.1 (0.6) | 0.0 (0.6)   | -0.0 (0.5)| -0.0 (0.5)      |           |             |           |                 |
| Weeks 45–48 | n |               | 116       | 109         | 126       | 117             |           |             |           |                 |
|             |   |               | 1.9 (2.7) | 1.7 (3.1)   | 1.8 (2.6) | 2.0 (2.7)       |           |             |           |                 |
|             |   |               | 2.0 (2.9) | 1.7 (3.1)   | 1.8 (2.7) | 1.9 (2.5)       |           |             |           |                 |
|             |   |               | 0.1 (0.6) | 0.0 (0.4)   | 0.1 (0.4) | 0.0 (0.7)       |           |             |           |                 |
| Weeks 49–52 | n |               | 106       | 113         | 113       | 111             |           |             |           |                 |
|             |   |               | 2.1 (3.2) | 1.6 (3.0)   | 1.8 (2.6) | 1.8 (2.5)       |           |             |           |                 |
|             |   |               | 2.2 (3.4) | 1.7 (3.1)   | 1.8 (2.7) | 1.8 (2.7)       |           |             |           |                 |
|             |   |               | 0.1 (0.8) | 0.1 (0.4)   | 0.1 (0.4) | 0.0 (0.7)       |           |             |           |                 |

*Daily rescue medication (short-acting β2-agonist) use included salbutamol and albuterol and was defined as occasions/day. Patients with ≥7 days eDiary data for both 2-week periods were included in the analysis of each individual dosing period. SD, standard deviation.
Table S4. Mean eDiary-assessed symptom scores during the individual dosing periods of the DREAM study

| Dosing period | Placebo (n=155) | 75 mg (n=153) | Mepolizumab 250 mg (n=152) | 750 mg (n=156) |
|---------------|-----------------|---------------|-----------------------------|----------------|
| **Weeks 1–4** |                 |               |                             |                |
| **First 2 weeks** | 147             | 142           | 149                         | 147            |
| Mean (SD)     | 1.7 (1.1)       | 1.5 (1.1)     | 1.6 (1.2)                   | 1.5 (1.2)      |
| **Next 2 weeks** | 1.5 (1.2)       | 1.4 (1.2)     | 1.5 (1.2)                   | 1.3 (1.2)      |
| Mean change (SD) | -0.2 (0.6)     | -0.1 (0.5)    | -0.1 (0.5)                  | -0.2 (0.5)     |
| **Weeks 5–8** |                 |               |                             |                |
| **First 2 weeks** | 142             | 141           | 142                         | 145            |
| Mean (SD)     | 1.4 (1.2)       | 1.3 (1.1)     | 1.4 (1.2)                   | 1.3 (1.2)      |
| **Next 2 weeks** | 1.5 (1.3)       | 1.3 (1.1)     | 1.4 (1.2)                   | 1.3 (1.2)      |
| Mean change (SD) | 0.0 (0.5)       | -0.0 (0.5)    | 0.0 (0.5)                   | -0.0 (0.4)     |
| **Weeks 9–12** |                 |               |                             |                |
| **First 2 weeks** | 137             | 135           | 136                         | 137            |
| Mean (SD)     | 1.3 (1.2)       | 1.2 (1.1)     | 1.4 (1.2)                   | 1.2 (1.2)      |
| **Next 2 weeks** | 1.4 (1.2)       | 1.2 (1.1)     | 1.4 (1.2)                   | 1.2 (1.2)      |
| Mean change (SD) | 0.1 (0.6)       | -0.0 (0.4)    | 0.0 (0.4)                   | 0.0 (0.4)      |
| **Weeks 13–16** |                 |               |                             |                |
| **First 2 weeks** | 133             | 133           | 135                         | 138            |
| Mean (SD)     | 1.4 (1.2)       | 1.2 (1.2)     | 1.4 (1.2)                   | 1.2 (1.2)      |
| **Next 2 weeks** | 1.4 (1.2)       | 1.2 (1.2)     | 1.5 (1.2)                   | 1.2 (1.2)      |
| Mean change (SD) | 0.0 (0.5)       | 0.0 (0.4)     | 0.1 (0.4)                   | 0.0 (0.3)      |
| **Weeks 17–20** |                 |               |                             |                |
| **First 2 weeks** | 132             | 130           | 133                         | 134            |
| Mean (SD)     | 1.3 (1.1)       | 1.1 (1.1)     | 1.3 (1.2)                   | 1.1 (1.2)      |
| **Next 2 weeks** | 1.2 (1.1)       | 1.1 (1.1)     | 1.3 (1.2)                   | 1.1 (1.1)      |
| Mean change (SD) | -0.1 (0.6)      | 0.0 (0.3)     | -0.0 (0.3)                  | 0.0 (0.4)      |
| **Weeks 21–24** |                 |               |                             |                |
| **First 2 weeks** | 118             | 122           | 126                         | 134            |
| Mean (SD)     | 1.2 (1.2)       | 1.0 (1.1)     | 1.4 (1.2)                   | 1.2 (1.2)      |
| **Next 2 weeks** | 1.3 (1.2)       | 1.1 (1.1)     | 1.4 (1.2)                   | 1.2 (1.2)      |
| Mean change (SD) | 0.0 (0.4)       | 0.0 (0.3)     | 0.0 (0.3)                   | 0.0 (0.5)      |
| **Weeks 25–28** |                 |               |                             |                |
| **First 2 weeks** | 130             | 122           | 127                         | 126            |
| Weeks          | n  | First 2 weeks | Mean (SD) | Next 2 weeks | Mean (SD) | Mean change (SD) | Mean (SD) | Next 2 weeks | Mean (SD) | Mean change (SD) |
|----------------|-----|---------------|-----------|--------------|-----------|------------------|-----------|--------------|-----------|------------------|
| 29–32          | 124 | 1.2 (1.1)     | 1.1 (1.1) | 1.3 (1.2)    | 1.1 (1.1) | -0.0 (0.3)       | 1.3 (1.3) | 1.2 (1.2)    | 1.3 (1.2) | 0.0 (0.4)       |
| 33–36          | 120 | 1.2 (1.1)     | 1.1 (1.1) | 1.3 (1.2)    | 1.1 (1.1) | -0.0 (0.3)       | 1.3 (1.2) | 1.2 (1.2)    | 1.3 (1.2) | 0.0 (0.3)       |
| 37–40          | 119 | 1.3 (1.2)     | 1.1 (1.1) | 1.3 (1.2)    | 1.1 (1.1) | 0.0 (0.3)        | 1.3 (1.2) | 1.2 (1.2)    | 1.3 (1.2) | 0.0 (0.4)       |
| 41–44          | 119 | 1.3 (1.2)     | 1.0 (1.0) | 1.3 (1.2)    | 1.1 (1.1) | -0.0 (0.3)       | 1.3 (1.2) | 1.2 (1.2)    | 1.3 (1.2) | 0.0 (0.3)       |
| 45–48          | 116 | 1.2 (1.2)     | 1.0 (1.0) | 1.3 (1.2)    | 1.1 (1.1) | 0.0 (0.3)        | 1.3 (1.2) | 1.2 (1.2)    | 1.3 (1.2) | 0.0 (0.3)       |
| 49–52          | 106 | 1.2 (1.2)     | 1.0 (1.1) | 1.2 (1.2)    | 1.1 (1.1) | 0.0 (0.3)        | 1.3 (1.2) | 1.2 (1.2)    | 1.3 (1.2) | 0.0 (0.3)       |

Patients with ≥7 days eDiary data for both 2-week periods were included in the analysis of each individual dosing period.
SD, standard deviation.
Figure S1. Mean eDiary-assessed change in peak expiratory flow (L/min) during the second 2 weeks compared with the first 2 weeks during the individual dosing periods in the DREAM study.
Figure S2. Mean eDiary-assessed change in symptom score during the second 2 weeks compared with the first 2 weeks during the individual dosing periods in the DREAM study.
Figure S3. Mean eDiary-assessed change in daily rescue medication use during the second 2 weeks compared with the first 2 weeks during the individual dosing periods in the DREAM study.